• Sumayah Abdul-Jabbar, Ian Bates, Graham Davies, and Rob Shulman.
• Institute of Pharmaceutical Science, King's College London, London, UK. Electronic address: sumayah.abdul-jabbar@kcl.ac.uk.
• J Crit Care. 2014 Jun 1;29(3):472.e7-12.

PurposeTo evaluate the costs of medicines used to treat critically ill patients in an intensive care environment and to correlate this with severity of illness and mortality.Materials And MethodsThe study was conducted at a London Teaching Hospital Critical Care Unit. Data were collected for patients who were either discharged or died during September 2011 and stayed longer than 48 hours. The drug cost was related to 150 drugs that were then related to patient's acuity and outcome.ResultsThe median daily drug cost of the 85 patients was £26. The highest cost patients in the 85th percentile had significantly higher daily drug costs (median, £403) and higher scores for patient acuity. Patients with hematologic malignancy had a median daily drug cost (£561) more than 20 times higher than those without. A regression analysis based on patient's diversity explained 93% of the variance in the daily drug cost.ConclusionsAlthough the median daily drug cost for an adult critically ill patient was low, this cost significantly escalated with patient acuity and hematologic malignancy. A reference method has been designed for an in-depth evaluation of daily drug cost that could be used to compare expenditure in other units.Copyright © 2014 Elsevier Inc. All rights reserved.

26 keywords...

hide…